NCT03196206View on ClinicalTrials.gov

Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 13, 2017

Primary Completion Date

March 4, 2018

Study Completion Date

March 4, 2018

Conditions
Thrombosis
Interventions
DRUG

BMS-986177

Oral Suspension

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology Of Miami Inc., Miami

Clinical Pharmacology of Miami LLC, Miami

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03196206 - Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment | Biotech Hunter | Biotech Hunter